Verici Dx plc (LON:VRCI – Get Free Report)’s stock price traded up 15.3% during trading on Monday . The stock traded as high as GBX 6.98 ($0.09) and last traded at GBX 6.98 ($0.09). 179,121 shares changed hands during trading, a decline of 49% from the average session volume of 354,601 shares. The stock had previously closed at GBX 6.05 ($0.08).
Verici Dx Price Performance
The firm has a market capitalization of £16.92 million, a price-to-earnings ratio of -125.00 and a beta of 1.53. The company has a current ratio of 2.58, a quick ratio of 8.49 and a debt-to-equity ratio of 9.28. The business has a 50-day moving average price of GBX 7.40 and a two-hundred day moving average price of GBX 8.74.
About Verici Dx
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
Featured Articles
- Five stocks we like better than Verici Dx
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- 5 discounted opportunities for dividend growth investors
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
